Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030

Summary

Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.

According to APO Research, The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

North American market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) include Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee and Fluxion, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), also provides the value of main regions and countries. Of the upcoming market potential for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) segment by Company

Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) segment by Type

CellSearch
Others
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) segment by Application

Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) key companies, revenue, market share, and recent developments.
3. To split the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) significant trends, drivers, influence factors in global and regions.
6. To analyze Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry.
Chapter 3: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.